Portfolio Case
  • ·Ph.D. at Karolinska Institutet.  
    ·

    Former Senior Scientist in AstraZeneca, Senior Associate in Department of Strategic Investment in a well-known listed company.  

    ·

    Overseas High-Level Talent of Shenzhen City Peacock Program.

    ·

    Has a few high impact publications in top journals such as Cell, Science Translational Medicine, Diabetes, Cell Death & Disease etc. Has insightful views to biopharma and biotech industry.


  • ·

    Postdoctoral fellow of harvard medical school

    ·

    He has been a domestic and international investment consultant for new drugs, and has published many papers as the first author in well-known academic journals such as Nature






  • ·

    M.S. from University of Liverpool

    ·

    Got 10 Million+ investment from SBCVC for the company founded by her own

    ·

    Ever worked for Zero2Ipo Group's reaserach center. Rich experience and resources in investment business


  • ·B.S. in resource science and Engineering at South China University of Technology; MBA at China Resources University.
    ·Served as a manager at 999 pharmaceuticals and China resources financial group. 
    ·Over 10 years of experience in Pharmaceutical industry and finance. Managed a private equity fund of 5 billion RMB and help public companies with M&A. 





  • ·Postdoctoral fellow at Stanford University.
    ·

    Former head of external innovation at Novartis; Won Novartis team innovation award twice. 

    ·

    Over 20 years of pharmaceutical industry experience.

    ·

    Has published numerous research papers on world renowned journals such as Cell, Development, Genome research and etc.


  • ·

    M.D. at The West China College of Medicine; Ph.D. in Pharmaceutical Sciences at Sichuan University
    ·Over 10-years experiences in development and investment of medical device. 
    ·Part of the core research team of long-acting anti-AIDS drug “Albuvirtide” and diabetes AMD drug “Conbercept”. Rich experience in oversea CRO/Pharma/Biotech.

     

  • ·Ph.D. in chemistry at University of Hong Kong with Ph.D. in Chemistry. CFA candidate.
    ·Served as the investment director in a domestic well-known Capital Management company; Participated in deal sourcing, due diligence and post-investment management.
    ·Worked in the investment banking department in National Gold Securities. She also participated in IPO industrial research, supplier development and profitability analysis.


  • ·doctor of microbiology, Chinese academy of sciences.
    ·co-founder of kedi health.
    ·obtained RMB 12 million in financing for the company, and published an article in nature magazine.


  • ·

    Sun yat-sen university & kansai university, Japan

    ·

    Pharmaceutical molecular biology and financial complex background

    ·

    He used to work in domestic well-known medical investment machinery and industry






  • ·

    Doctor of pharmaceutical chemistry, university of Paris, France

    ·

    Previously worked in a well-known pharmaceutical research and development CRO/CDMO company, specializing in innovative drug research and development









  • ·

    Shanghai jiao tong university pharmacy major bachelor minor law investment

    ·

    He used to be the investment manager of China finance and financial holding co., ltd. and China innovation investment co., LTD. He successfully invested in pharmaceutical projects such as Marine and biological projectsPreviously worked in a well-known pharmaceutical research and development CRO/CDMO company, specializing in innovative drug research and development











  • ·

    Doctor of chemistry, university of Texas at Austin

    ·

    A founding partner of Replix Research Group, familiar with FDA rules and successfully excavated Viking, Zogenix, Corium, etc


  • ·

    PhD in biochemistry, CFA candidate, university of Oxford

    ·

    The doctoral entrepreneurship program I established once won the first prize of the national entrepreneurship competition. I once worked as an intern in a well-known domestic securities firm and deeply participated in the analysis of the pharmaceutical industry









  • ·

    Sun yat-sen university molecular medicine doctor

    ·

    He served as a postdoctoral researcher and assistant researcher in the school of medicine, sun yat-sen university, focusing on molecular immunology, tumor immunology, metabolomics and other fields





  • ·

    BSc in Biomedical Science at Imperial College London

    ·

    MSc in Chinese University of Hong Kong


Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务